<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-91122" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neonatal Myasthenia Gravis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bardhan</surname>
            <given-names>Mainak</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dogra</surname>
            <given-names>Hansa</given-names>
          </name>
          <aff>Pt B.D Sharma Post Graduate Institute of Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Samanta</surname>
            <given-names>Debopam</given-names>
          </name>
          <aff>University of Arkansas for Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mainak Bardhan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hansa Dogra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Debopam Samanta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>9</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-91122.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neonatal myasthenia gravis (MG) is a temporary form of MG. Babies born to mothers with MG are susceptible to it. This is due to the mother&#x02019;s antibodies cross over to the baby. This activity reviews the evaluation and management of neonatal MG and highlights the role of the healthcare team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the etiology of neonatal myasthenia gravis.</p></list-item><list-item><p>Assess&#x000a0;the pathophysiology of neonatal myasthenia gravis.</p></list-item><list-item><p>Evaluate&#x000a0;the typical presentation of a patient with neonatal myasthenia gravis.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration among the interprofessional team to ensure the appropriate management for neonatal myasthenia gravis to enhance management during the neonatal period.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=91122&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=91122">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-91122.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Myasthenia gravis (MG), a neuromuscular junction disorder, causes weakness in the body's voluntary muscles, involving eyes, mouth, throat, arms, and legs. It usually affects adults, but it can sometimes happen in children. Neonatal MG is a distinct type of MG. Although there are similarities in the pathophysiology and clinical features with the adult counterpart of the disease, neonatal MG has many distinct features.<xref ref-type="bibr" rid="article-91122.r1">[1]</xref>&#x000a0; These considerations underscore the need to discuss the disease separately from its adult counterpart. Neonatal MG &#x000a0;is a temporary form of MG. Babies born to mothers with&#x000a0;MG are susceptible to it. It&#x02019;s due to the mother&#x02019;s antibodies crossing over to the baby. As the name suggests, it usually lasts only a short time. The symptoms disappear weeks or months after birth as the antibodies are naturally replaced. Babies are not at greater risk of developing MG later in life. This is distinct from congenital MG, a very rare form of MG, which&#x000a0;is an autosomal recessive disease originating from rare genetic disorders. Symptoms of congenital MG usually start at birth and are lifelong. Neonatal MG is also distinct from juvenile MG, the most common form of MG in childhood, and clinically identical to adult autoimmune MG patients. However, juvenile MG patients do not present in the neonatal age group, and the earliest presentation&#x000a0;has been reported in late infancy.</p>
      </sec>
      <sec id="article-91122.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>This is an autoimmune disorder and affects neonates born to mothers with autoimmune MG. Neonatal MG occurs due to the transplacental passage of antibodies directed against various neuromuscular junction antigens. The most common antigen is&#x000a0;the nicotinic acetylcholine receptor (AChR). Another important antigen is the muscle-specific receptor tyrosine kinase (MuSKR).</p>
      </sec>
      <sec id="article-91122.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of&#x000a0;MG&#x000a0;in the general population ranges from 1.7&#x000a0;TO 30.0 cases per million person-years, with a prevalence of 77.7 cases per million persons.<xref ref-type="bibr" rid="article-91122.r2">[2]</xref><xref ref-type="bibr" rid="article-91122.r3">[3]</xref>&#x000a0;A meta-analysis concluded that the incidence of juvenile MG is approximately between 1.0 and 5.0 cases per million person-years.<xref ref-type="bibr" rid="article-91122.r2">[2]</xref>&#x000a0;Pediatric patients were found to make up approximately 10%&#x000a0;TO 15% of all patients with autoimmune&#x000a0;MG in a prevalence study in Virginia.<xref ref-type="bibr" rid="article-91122.r4">[4]</xref>&#x000a0;Among Asian populations, there appears to be a higher prevalence of JMG compared to white populations, with JMG representing 50% of all autoimmune&#x000a0;MG. Epidemiological data specific to neonatal MG is scarce.<xref ref-type="bibr" rid="article-91122.r5">[5]</xref><xref ref-type="bibr" rid="article-91122.r6">[6]</xref><xref ref-type="bibr" rid="article-91122.r7">[7]</xref>&#x000a0;Due to poor detection rate and difficulty with clinical identification of neonatal MG in mildly affected infants, underreporting this MG is likely.&#x000a0;In general, neonatal MG is noted to be rare and may present in&#x000a0;10% to 15% of&#x000a0;newborns born to mothers with MG. However, the risk of neonatal MG in a sibling is significantly higher in subsequent pregnancies. There is no reported race or gender preference. There is no&#x000a0;definite association&#x000a0;between the mother's disease severity and the newborn's clinical presentation.&#x000a0;</p>
      </sec>
      <sec id="article-91122.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Neonatal&#x000a0;MG is an antibody-mediated disorder caused by the transplacental transmission of maternal antibodies. Approximately three-quarters of the mothers with MG possess anti-acetylcholine receptor (anti-AChR) antibodies.&#x000a0;These circulating maternal autoantibodies cross the placenta to the fetus. They are responsible for&#x000a0;nicotinic acetylcholine receptor loss by&#x000a0;speeding up their degradation, blocking acetylcholine binding, and&#x000a0;prompting the lysis of the postsynaptic membrane through&#x000a0;activation of the complement system. This leads to an affected child after birth(rarely before birth with decreased fetal movements and the formation of arthrogryposis multiplex congenita and decreased fetal swallowing and polyhydramnios). The antibodies can be directed against the fetus (present until 33 weeks gestation) or the adult acetylcholine receptor. Children of mothers who have&#x000a0;MG develop neonatal&#x000a0;MG approximately 5% to 30% of the time.<xref ref-type="bibr" rid="article-91122.r8">[8]</xref><xref ref-type="bibr" rid="article-91122.r9">[9]</xref></p>
      </sec>
      <sec id="article-91122.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The neonates become symptomatic 3 to 72 hours after birth. Most symptomatic babies have&#x000a0;poor sucking, respiratory distress, and generalized hypotonia in association with a weak cry and facial diplegia. Gavage feeding&#x000a0;for swallowing difficulties and ventilator support due to breathing difficulties can be necessary in severe cases. In contrast to older children, ptosis (may be unilateral, bilateral, and symmetric) and ophthalmoplegia are relatively uncommon in neonatal MG.<xref ref-type="bibr" rid="article-91122.r6">[6]</xref><xref ref-type="bibr" rid="article-91122.r10">[10]</xref><xref ref-type="bibr" rid="article-91122.r11">[11]</xref>&#x000a0;Atypical and severe presentation of neonatal MG can be of arthrogryposis multiplex congenita with the development of multiple joint contractures. However, most neonates completely recover before 4 months, and more than 90% even before 2 months. This improvement correlates with the disappearance of maternal antibodies. Pure ocular&#x000a0;MG is not seen in neonatal MG, which&#x000a0;is more common in children than adults and tends to occur more often in prepubertal children. In contrast, generalized MG is more common in postpubertal adolescents.<xref ref-type="bibr" rid="article-91122.r12">[12]</xref><xref ref-type="bibr" rid="article-91122.r9">[9]</xref><xref ref-type="bibr" rid="article-91122.r13">[13]</xref>&#x000a0;The physical examination in neonates with MG can be significant for the frog-leg position suggestive of diffuse hypotonia. An open mouth and apparent ptosis can help diagnose this condition. Flabby muscles and prominent head lags are common. Deep&#x000a0;tendon reflexes are generally intact, but primitive reflexes can be difficult to elicit or absent.</p>
      </sec>
      <sec id="article-91122.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Neonatal MG, like adult MG, is ultimately a clinical diagnosis. A strongly suggestive history (mother with known autoimmune MG) and physical examination may be sufficient to make the diagnosis; however, in&#x000a0;rare cases, the clinical presentation is not classic,&#x000a0;and the mother is asymptomatic for MG, and it is usually helpful to have positive results on&#x000a0;1 or more standard diagnostic tests.</p>
        <p>
<bold>Antibody Testing for Anti-acetylcholine Receptor</bold>
</p>
        <p>Antibody testing is usually highly specific for MG. In the appropriate clinical setting, positive antibody titers confirm the diagnosis and further testing may only be indicated if the clinical presentation is atypical. Antibody testing only involves serum testing and is relatively inexpensive and straightforward, especially in the case of acetylcholine receptor antibodies.&#x000a0;</p>
        <p>
<bold>Intramuscular Neostigmine Test</bold>
</p>
        <p>Intramuscular neostigmine can be administered to evaluate the response of ptosis, dysphagia, and head lag. In the case of negative or equivocal results, a second dose can be administered after 4 hours.&#x000a0;It is best if this testing is performed in a monitored setting (ie, with cardiac telemetry) where advanced cardiorespiratory support is available in case of bradycardia or asystole, which in rare instances occurs during this testing, especially when higher doses are used. Other adverse effects are abdominal cramps, sudden diarrhea, cardiac arrhythmia, and excessive tracheobronchial secretions. Intravenous neostigmine is contraindicated before 2 years of age due to&#x000a0;the risk of cardiac arrhythmia.&#x000a0;</p>
        <p>
<bold>Electromyogram/Nerve Conduction Study (EMG/NCS)</bold>
</p>
        <p>This test measures the electrical activity of a muscle or a group of muscles. In some cases, a single-fiber EMG test may be done, which is a more sensitive test. Traditional single-fiber electromyography is not practical for most children, especially as it cannot be performed under sedation or general anesthesia. A variant of single-fiber electromyography, stimulated single-fiber electromyography, is much more helpful in children and adolescents than traditional single-fiber electromyography.<xref ref-type="bibr" rid="article-91122.r14">[14]</xref>&#x000a0;A 10% decremental response in the amplitude of the compound muscle action potential with repetitive nerve stimulation can be helpful in the diagnosis but is usually not performed in neonates in most centers.</p>
      </sec>
      <sec id="article-91122.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Medical therapies for neonatal&#x000a0;MG&#x000a0;differ from those for juvenile MG, including chronic pharmacotherapy to increase the availability of acetylcholine neurotransmitters and immunomodulatory and immunosuppressive drugs.<xref ref-type="bibr" rid="article-91122.r14">[14]</xref>&#x000a0;Immunomodulation and immunosuppression are more powerful approaches to medical therapy. However, immunomodulation and immunosuppression are typically more invasive or carry greater side effect burdens.<xref ref-type="bibr" rid="article-91122.r15">[15]</xref><xref ref-type="bibr" rid="article-91122.r16">[16]</xref>&#x000a0;As in adults, pediatric patients and their families should be counseled regarding medications that may exacerbate MG.<xref ref-type="bibr" rid="article-91122.r17">[17]</xref>&#x000a0;In the neonatal age group, the use of aminoglycoside should be given particular importance, as it may potentiate symptoms of MG. However, for neonatal MG, the treatment lasts, if necessary, only for a few days to a few months. If mildly symptomatic, small and frequent feeding is necessary with proper surveillance for aspiration and dysphagia. In more severe cases, oral or IM neostigmine may be necessary, as well as gavage feeding. Administration of neostigmine 30 minutes before feeding can help with dysphagia. Pyridostigmine (a slightly longer-acting agent) can be used alternatively. Fortunately, plasmapheresis, intravenous immunoglobulins, and corticosteroids are all efficacious in treating MG in older children and adults but rarely are needed and only necessary for managing&#x000a0;severely affected&#x000a0;neonates for rapid removal of circulating antibodies.<xref ref-type="bibr" rid="article-91122.r18">[18]</xref><xref ref-type="bibr" rid="article-91122.r19">[19]</xref>&#x000a0;Infants born to mothers who have taken corticosteroids during pregnancy should be monitored for adrenal inefficiencies during the newborn period.&#x000a0;This topic focuses on neonatal MG, and thymectomy is not necessary for these patients. Please refer to numerous retrospective pediatric studies that indicate that thymectomy is potentially beneficial for juvenile MG.<xref ref-type="bibr" rid="article-91122.r20">[20]</xref><xref ref-type="bibr" rid="article-91122.r21">[21]</xref><xref ref-type="bibr" rid="article-91122.r22">[22]</xref><xref ref-type="bibr" rid="article-91122.r10">[10]</xref><xref ref-type="bibr" rid="article-91122.r23">[23]</xref></p>
      </sec>
      <sec id="article-91122.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The following conditions mimic neonatal MG:</p>
        <list list-type="bullet">
          <list-item>
            <p>Spinal muscular atrophy</p>
          </list-item>
          <list-item>
            <p>Congenital MG</p>
          </list-item>
          <list-item>
            <p>Morphologically distinct congenital myopathies like central core disease, nemaline myopathy, and myotubular myopathy.</p>
          </list-item>
          <list-item>
            <p>Congenital muscular dystrophies</p>
          </list-item>
          <list-item>
            <p>Limb-girdle or facioscapulohumeral muscular dystrophy</p>
          </list-item>
          <list-item>
            <p>Infantile myotonic dystrophy</p>
          </list-item>
          <list-item>
            <p>Mitochondrial myopathy</p>
          </list-item>
          <list-item>
            <p>Brainstem anomaly</p>
          </list-item>
          <list-item>
            <p>Mobius syndrome</p>
          </list-item>
          <list-item>
            <p>Congenital fibrosis of extraocular muscles</p>
          </list-item>
          <list-item>
            <p>Infantile botulism</p>
          </list-item>
          <list-item>
            <p>Seropositive and seronegative forms of autoimmune&#x000a0;MG</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-91122.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The outcome in the classical form of neonatal&#x000a0;MG is excellent, assuming appropriate respiratory and nutritional support. Severe and rare variants of this disease cause long-term complications in neonates born with MG. Most patients experience spontaneous remission after weeks to months.</p>
      </sec>
      <sec id="article-91122.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Traditionally, neonatal&#x000a0;MG has been regarded as a relatively benign disease with few to no long-term consequences when properly treated. However, more severe variants associated with long-term medical consequences have been described, including the fetal acetylcholine receptor inactivation syndrome. Thus, these variants should be considered in the differential diagnosis of children with unexplained muscle weakness in the setting of distinct clinical features associated with these forms of neonatal MG.</p>
      </sec>
      <sec id="article-91122.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Pediatric&#x000a0;MG can present as neonatal&#x000a0;MG (congenital myasthenic syndromes, transient neonatal MG) or during adolescence (juvenile MG). The latter is an autoimmune disease that can have a variable presentation. If a mother has a neonate with transient MG, her subsequent babies are&#x000a0;at higher risk of developing transient MG. However, the duration and severity of MG in the mother are not predictive of the development of neonatal MG. So, all deliveries should be conducted in a tertiary birth center. Symptoms can be variable, ranging from mild ophthalmic symptoms, such as isolated fatigable ptosis, to myasthenic crises involving the respiratory muscles, requiring ventilator support. Making a formal diagnosis of the disease can be difficult, but when suspicion is raised for a fatigable deficit, appropriate diagnostic testing&#x000a0;should&#x000a0;be pursued. Treatments should be tailored to the subtype of disease and the severity of illness. Variable responses to medications and surgical interventions can be seen between patients.<xref ref-type="bibr" rid="article-91122.r19">[19]</xref>&#x000a0;Children with&#x000a0;MG do not tolerate neuromuscular blocking drugs, such as succinylcholine and pancuronium, and may be paralyzed for weeks after a single dose. An anesthesiologist should carefully review myasthenic patients who require a surgical anesthetic, and such anesthetics should be administered only by an experienced physician/anesthesiologist. Also, certain antibiotics can potentiate myasthenia and should be avoided; these include aminoglycosides, beta-blocking agents, procainamide, chloroquine, and fluoroquinolones.<xref ref-type="bibr" rid="article-91122.r22">[22]</xref>&#x000a0;A pediatric ophthalmologist should follow children with involvement of the extraocular musculature to monitor for ophthalmic complications associated with JMG.</p>
      </sec>
      <sec id="article-91122.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>There has been&#x000a0;no correlation between neonatal MG and the maternal&#x000a0;antibody titer.&#x000a0;Moreover, the duration of&#x000a0;MG in the mother and the use of medicines for MG have not been correlated with the occurrence of neonatal MG. To optimize the care of these patients, the interprofessional team should include perinatologists, neonatologists, and specialty-trained nurses.</p>
      </sec>
      <sec id="article-91122.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=91122&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=91122">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/neonatal-myasthenia-gravis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=91122">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/91122/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=91122">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-91122.s15">
        <title>References</title>
        <ref id="article-91122.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiang</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Darras</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Juvenile myasthenia gravis.</article-title>
            <source>Muscle Nerve</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-31</page-range>
            <pub-id pub-id-type="pmid">19229875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGrogan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sneddon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>The incidence of myasthenia gravis: a systematic literature review.</article-title>
            <source>Neuroepidemiology</source>
            <year>2010</year>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-83</page-range>
            <pub-id pub-id-type="pmid">20130418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carr</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cardwell</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>McCarron</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>McConville</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of population based epidemiological studies in Myasthenia Gravis.</article-title>
            <source>BMC Neurol</source>
            <year>2010</year>
            <month>Jun</month>
            <day>18</day>
            <volume>10</volume>
            <fpage>46</fpage>
            <pub-id pub-id-type="pmid">20565885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Torner</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of myasthenia gravis in central and western Virginia.</article-title>
            <source>Neurology</source>
            <year>1992</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>10</issue>
            <fpage>1888</fpage>
            <page-range>1888-93</page-range>
            <pub-id pub-id-type="pmid">1407568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>YL</given-names>
              </name>
            </person-group>
            <article-title>Myasthenia gravis in Hong Kong Chinese. 2. Paediatric disease.</article-title>
            <source>Acta Neurol Scand</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>86</volume>
            <issue>1</issue>
            <fpage>68</fpage>
            <page-range>68-72</page-range>
            <pub-id pub-id-type="pmid">1519477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gamio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garcia-Erro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vaccarezza</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Minella</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Myasthenia gravis in childhood.</article-title>
            <source>Binocul Vis Strabismus Q</source>
            <year>2004</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>223</fpage>
            <page-range>223-31</page-range>
            <pub-id pub-id-type="pmid">15530139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haliloglu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Anlar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aysun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Topcu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Topaloglu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Turanli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yalnizoglu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Gender prevalence in childhood multiple sclerosis and myasthenia gravis.</article-title>
            <source>J Child Neurol</source>
            <year>2002</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>390</fpage>
            <page-range>390-2</page-range>
            <pub-id pub-id-type="pmid">12150589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrews</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Massey</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis.</article-title>
            <source>Neurology</source>
            <year>1994</year>
            <month>Jul</month>
            <volume>44</volume>
            <issue>7</issue>
            <fpage>1208</fpage>
            <page-range>1208-14</page-range>
            <pub-id pub-id-type="pmid">8035917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Batocchi</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bartoccioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lino</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Minisci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tonali</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Juvenile myasthenia gravis with prepubertal onset.</article-title>
            <source>Neuromuscul Disord</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>561</fpage>
            <page-range>561-7</page-range>
            <pub-id pub-id-type="pmid">10093062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MILLICHAP</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>DODGE</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of myasthenia gravis in infancy, childhood, and adolescence: a study of 51 patients.</article-title>
            <source>Neurology</source>
            <year>1960</year>
            <month>Nov</month>
            <volume>10</volume>
            <fpage>1007</fpage>
            <page-range>1007-14</page-range>
            <pub-id pub-id-type="pmid">13770917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jayawant</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune myasthenia gravis.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2013</year>
            <volume>113</volume>
            <fpage>1465</fpage>
            <page-range>1465-8</page-range>
            <pub-id pub-id-type="pmid">23622368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanderPluym</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vajsar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Mah</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Grenier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kolski</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics of pediatric myasthenia: a surveillance study.</article-title>
            <source>Pediatrics</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>132</volume>
            <issue>4</issue>
            <fpage>e939</fpage>
            <page-range>e939-44</page-range>
            <pub-id pub-id-type="pmid">24019417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heckmann</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van Toorn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lubbe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Janse van Rensburg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wilmshurst</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The characteristics of juvenile myasthenia gravis among South Africans.</article-title>
            <source>S Afr Med J</source>
            <year>2012</year>
            <month>May</month>
            <day>23</day>
            <volume>102</volume>
            <issue>6</issue>
            <fpage>532</fpage>
            <page-range>532-6</page-range>
            <pub-id pub-id-type="pmid">22668957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Neurophysiological strategies for the diagnosis of disorders of the neuromuscular junction in children.</article-title>
            <source>Dev Med Child Neurol</source>
            <year>2008</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>328</fpage>
            <page-range>328-33</page-range>
            <pub-id pub-id-type="pmid">18312422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skeie</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Apostolski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Evoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilhus</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Illa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Harms</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hilton-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Melms</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verschuuren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horge</surname>
                <given-names>HW</given-names>
              </name>
              <collab>European Federation of Neurological Societies</collab>
            </person-group>
            <article-title>Guidelines for treatment of autoimmune neuromuscular transmission disorders.</article-title>
            <source>Eur J Neurol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>893</fpage>
            <page-range>893-902</page-range>
            <pub-id pub-id-type="pmid">20402760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liew</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Update on juvenile myasthenia gravis.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>694</fpage>
            <page-range>694-700</page-range>
            <pub-id pub-id-type="pmid">24141560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grammer</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Drugs that may exacerbate myasthenia gravis.</article-title>
            <source>Ann Emerg Med</source>
            <year>1984</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>532</fpage>
            <page-range>532-8</page-range>
            <pub-id pub-id-type="pmid">6742556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000f6;ls</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Liersch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leistner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gellert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schalke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niedobitek</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus.</article-title>
            <source>Ann Neurol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>515</fpage>
            <page-range>515-8</page-range>
            <pub-id pub-id-type="pmid">21905083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batocchi</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Evoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palmisani</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Lo Monaco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bartoccioni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tonali</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Early-onset myasthenia gravis: clinical characteristics and response to therapy.</article-title>
            <source>Eur J Pediatr</source>
            <year>1990</year>
            <month>Nov</month>
            <volume>150</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-8</page-range>
            <pub-id pub-id-type="pmid">2079081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liew</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Shamberger</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Weldon</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Darras</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis.</article-title>
            <source>JAMA Neurol</source>
            <year>2014</year>
            <month>May</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>575</fpage>
            <page-range>575-80</page-range>
            <pub-id pub-id-type="pmid">24590389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Theodorescu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Shandling</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Thymectomy in juvenile myasthenia gravis.</article-title>
            <source>J Child Neurol</source>
            <year>1990</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-8</page-range>
            <pub-id pub-id-type="pmid">2398237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Myasthenia gravis in children: long-term follow-up.</article-title>
            <source>Ann Neurol</source>
            <year>1983</year>
            <month>May</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>504</fpage>
            <page-range>504-10</page-range>
            <pub-id pub-id-type="pmid">6870202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91122.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gajdos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chevret</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2008</year>
            <volume>1132</volume>
            <fpage>271</fpage>
            <page-range>271-5</page-range>
            <pub-id pub-id-type="pmid">18096850</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
